Activist Shareholder Acquires 9% Stake... 'Vaccine Platform' Secures Major Pharmaceutical Partnerships

Activist fund Shah Capital disclosed it holds roughly a 9% stake in U.S. vaccine maker Novavax, Inc. (NASDAQ: NVAX). In its “Elevating Novavax” presentation, the firm directly criticizes management’s marketing strategy, the structure of its partnership with Sanofi, its capital markets approach, and its compensation framework, and calls for changes to the board and corporate governance.

In its Q1 fiscal 2026 results announced May 6, Novavax reported $140 million in revenue and a net loss of $9 million, while emphasizing its Matrix-M technology license agreement with Pfizer—under which it received a $30 million upfront payment and is eligible for up to $500 million in milestone payments—a $330 million loan facility with MidCap Financial, and approximately $795 million in cash and marketable securities.

Recently, Shah Capital has publicly opposed the re-election of certain board members and executive compensation proposals, warning it is prepared to wage a proxy fight if necessary. That activism has become visible in a short-term share price surge. Meanwhile, Sanofi’s Phase 4 COMPARE study comparing its vaccine Nuvaxovid with Moderna’s mNEXSPIKE reported a more favorable adverse-event profile for Nuvaxovid, renewing interest in Novavax’s protein-based vaccine technology.

Novavax, a U.S. biotech, has developed vaccines for infectious diseases including COVID-19 using its protein nanoparticle platform and proprietary Matrix-M adjuvant. It is now shifting from self-commercialization toward a platform business model, licensing its technology to global pharmaceutical partners such as Pfizer and Sanofi. With COVID-19 vaccine demand declining and revenues under pressure, the company is pursuing portfolio and revenue diversification in the competitive global vaccine market—where protein, mRNA, and other platforms vie for market share—through expanded licensing and collaboration agreements.